Skip to main content

Center for Integration of Science and Industry

Meet Our Team

Dr. Fred Ledley
Fred D. Ledley, MD

Fred D. Ledley, MD, is Director of the Center for Integration of Science and Industry at Bentley University, a Professor in the Department of Natural & Applied Sciences and Department of Management and a Member of Bentley’s Health Thought Leadership Network. A recognized opinion leader in the integration of basic science with medicine, business, society and education, he is the author of >200 published works in fields ranging from biotechnology business and finance to molecular human biology, drug development, bioethics and STEM education. Ledley has served on the faculties of the Howard Hughes Medical Institute and the Baylor College of Medicine, and was involved in founding biotechnology companies including GeneMedicine (IPO NASDAQ:GMED), serving as Vice President, R&D, and Variagenics (IPO NASDAQ:VGEN), serving as President & CEO. He has served on the Board of Directors of MassBIO, the Board of Overseers of Boston Children’s Hospital and as a consultant to industry, academia and government. He has a BS from the University of Maryland, an MD from Georgetown University, trained in Pediatrics at Boston Children’s Hospital and was an American Cancer Society fellow with Dr. David Baltimore at MIT.

View Dr. Ledley's Google Scholar profile

Dr. Matthew J. Jackson
Matthew J. Jackson, PhD

Matthew J. Jackson, PhD, is a Post-Doctoral Fellow at the Center for Integration of Science and Industry at Bentley University. He gained his PhD in Cellular Medicine from Newcastle University, UK, investigating effects of oxidative damage on cellular bioenergetics in the ageing skin. He also received his MSc in Stratified Medicine and Pharmacological Innovation from the University of Glasgow and his BSc in Pharmacology from the University of Dundee. In his first post-doctoral role, Dr. Jackson worked with Hexis Labs Ltd and Newcastle University in a Knowledge Transfer Partnership associate role, applying scientific experience to improve Hexis Lab Ltd productivity and profitability in their early stage business development. Starting at Bentley University in December 2019, his current research interests focus on trends in new drug discovery including funding of R&D and societal impact of pharmaceutical activity. In addition to his current research, Dr. Jackson also holds an adjunct professor role at Bentley University, teaching Human Biology within the department of Natural and Applied Sciences.

View Dr. Jackson's Google Scholar profile

Dr. Edward Zhou
Edward W. Zhou, PharmD

Edward W. Zhou, PharmD, is a Post-Doctoral Fellow at the Center for Integration of Science and Industry at Bentley University. He received his Doctor of Pharmacy degree from Massachusetts College of Pharmacy and Health Sciences, Boston, MA. He obtained a certificate from the MIT xPRO Drug and Medical Device Development Program. During his predoctoral internship, Edward worked with Pfizer Global Regulatory Affairs in organizing internal and public information databases for the pending FDA Oncologic Drugs Advisory Committee review. During his Newton-Wellesley Hospital rotation, Edward created adjustable python code packages for interpreting health outcome metrics from EPIC metadata. He has co-authored several peer-reviewed publications at Brigham and Women's Hospital, Harvard Medical School, which focus on the identification of drug targets and novel pharmacotherapeutics for neurological disorders. Starting at Bentley University in February 2021, his current research projects include the integration of research algorithms into existing database frameworks and the improvement of search field functionality and accuracy to expand the scope of future research projects.

Dr. Paula Chaves da Silva
Paula Chaves da Silva, PhD

Paula Chaves da Silva, PhD, is a Post-Doctoral Fellow at the Center for Integration of Science and Industry at Bentley University. She obtained both her PhD and her MS in Morphological Sciences from Federal University of Rio de Janeiro (UFRJ). During her doctorate internship, Dr. Chaves da Silva worked with adult neurogenesis and neurodegenerative events at Wellesley College in Wellesley, MA. In her first post-doctoral role, Dr. Chaves da Silva studied therapeutic strategies to treat neurodegenerative disorders from both basic research and clinical approaches. She obtained a certification in Neurofunctional Physical Therapy from Instituto de Neurologia Deolindo Couto – UFRJ, focusing on strength training in people with Parkinson’s Disease. As a National Science Foundation (NSF) supported Post-Doctoral Fellow in the Neuroscience Department at Wellesley College, Dr. Chaves da Silva managed a project on the relationship between adult neurogenesis and the immune system. Starting at Bentley University in September 2021, her current research focuses on health value created by biopharmaceutical companies, which includes the societal impact of pharmaceutical activity.  

Dr. Vineeta Tanwar
Vineeta Tanwar, PhD

Vineeta Tanwar, PhD, is a Post-Doctoral Fellow at the Center for Integration of Science and Industry at Bentley University. She received her PhD in Pharmacology, her MS in Pharmacology, and her BS in Human Biology from All India Institute of Medical Sciences, India. Dr. Tanwar conducted her prior post-doctoral research work at one of the Progenitor Cell Biology Consortium (PCBC) labs at Vanderbilt University where she exploited human and mouse embryonic stem cells to optimize cardiac repair and regeneration therapy. Dr. Tanwar has also worked in the field of Environmental Cardiology at Ohio State University where she collaborated with United States Department of Veterans Affairs, studying external triggers of cardiac diseases (such air pollution), and investigating the pulmonary and cardiovascular effects of World Trade Center (WTC) dust exposure. Starting at Bentley University in January 2022, her current research interests focus on identifying the state of drug innovation in the past decade (2010-2019) to obtain more informative insight into the drug innovation trend. 

Juliana Harrison
Juliana Harrison, MBA

Juliana Harrison, MBA, is Program Manager at the Center for Integration of Science and Industry at Bentley University. She received her MBA and BS in Marketing and Liberal Studies (Health and Industry) from Bentley. Her primary responsibilities consist of a variety of administrative, programming, and communications work to ensure smooth operation of the Center. This includes effective coordination and support of the Center’s meetings, events, filing system, publications, website, social media, and external relationships.

Dr. Michael Boss
Michael Boss, PhD, MBA

Michael Boss, PhD, MBA, is an Executive in Residence at the Center for Integration of Science and Industry at Bentley University. Boss has been a leader in the biotechnology industry for more than 30 years as a scientist and senior executive. As a group leader at Celltech, he was lead inventor of the landmark “Boss patent,” which enabled genetic engineering and manufacture of recombinant, monoclonal antibodies and generated >$1 billion in revenues. Dr. Boss co-founded Oros Instruments, a successful developer of protein purification equipment that was acquired by Biotage. He subsequently joined Genica Pharmaceuticals as Vice President of Research and Development and later Vice President of Operations, where he had a central role in building Genica (renamed Athena Diagnostics) into the leading developer of neurological and genetic tests and the first company to undertake DNA sequencing for human genetic testing. Later Boss held the position of Vice President, Corporate Office of Technology, at Elan Corporation and Chief Operating Officer of Xanthus Pharmaceuticals Inc., leading its acquisition by Antisoma, where he continued in senior executive positions. From 2012 to 2019, Boss led the program at Summit Therapeutics, Inc. as Chief Technology Officer to develop a therapy for Duchenne Muscular Dystrophy. Under his leadership the program progressed from pre-clinical to a proof-of-concept Phase 2 trial. Boss negotiated a license deal with Sarepta Therapeutics Inc. for European and Latin American commercial rights where Summit received $40 million upfront with a total potential deal value of some $941 million in milestone payments. He has a PhD and BSc from London University as well as an MBA from London Business School. He also trained in immunology at ICRF London with Dr. Mel Greaves and Dr. Martin Raff and was a post-doctoral fellow with Dr. David Baltimore at the Center for Cancer Research at MIT.

Nancy Hsiung, PhD

Nancy Hsiung, PhD, is an Executive in Residence at the Center for Integration of Science and Industry at Bentley University. She has more than 30 years of experience in the biotechnology industry, in both scientific and managerial positions as well as in the investment community.  For the past 11 years, Hsiung worked with GeneChem Management Inc, a venture fund headquartered in Montreal, where her responsibilities included sourcing, assessing and managing investment opportunities. Prior to GeneChem, Nancy was a consultant whose activities range from strategic planning, business development, technology assessment, market research and financing for biotechnology and biopharmaceutical companies. She started her career on the operational side as a scientist with Integrated Genetics (now part of Genzyme, now Sanofi) where she established the company's gene expression and tissue culture capabilities, as a member of the management team at Applied Biotechnology, whose focus was on vaccines and oncology and as the U.S. head of Corporate Development for Toyobo Corporation's (a large Japanese multinational) biopharmaceutical division. Hsiung received a BA degree from the University of Pennsylvania and a PhD degree in chemistry from Columbia University; she completed her post-doctoral studies in molecular biology at Yale University and Princeton University. She holds more than 15 patents and patent applications worldwide and has written 12 publications/abstracts.

Affiliated Faculty

ZoeZoë F. Wagner, PhD, is a Lecturer in the Department of Natural and Applied Sciences at Bentley University. She received her PhD in Pharmaceutical Sciences from the University of Southern California, her MS in Bioengineering and Biomedical Engineering from the University of Pennsylvania, her BEng in Bioengineering and Biomedical Engineering from Stevens Institute of Technology, and her BS in Chemistry from New York University. Dr. Wagner’s dissertation work focused on nanoparticle-based targeted drug delivery to the tumor microenvironment. Her collaborations with the Center for Integration of Science and Industry began in July 2017, and she is currently working on a quantitative measure of basic science innovation in new drug approvals. In the NAS Department, Dr. Wagner teaches Human Biology, The Biological Fate of Drugs, and Exploring the Microbiome.


Gregory Vaughan, PhD, is an Assistant Professor in the Department of Mathematical Sciences at Bentley University. He received his PhD in Statistics from the University of Connecticut and his BS in Mathematics and Computer Science from Trinity College. His research focuses on statistical learning and computing, longitudinal data analysis biostatistics, and applications to public health. Joining Bentley in July 2017, Dr. Vaughan teaches statistics, analytics, regression, and model selection. Since 2018, he has collaborated with the Center for Integration of Science and Industry on various projects examining profitability of pharmaceutical companies, technology maturation, and the drug development pipeline.

CliftonClifton M. Chow, PhD, PMP, is a Research Consultant with the Academic Technology Center at Bentley University. Clifton holds a PhD from Brandeis University, an MS from Johns Hopkins University, an EdM from Harvard University, and a BA from the University of California. Prior to joining Bentley in February 2019, he was a health economic outcomes researcher for consulting firms whose clients were federal and state health policy leaders as well as pharmaceutical and life sciences firms. His collaborations with the Center for Integration of Science and Industry began in May 2019, and he is currently working on projects involving Markov analysis. Trained as a health economist, he assists faculty with all aspects of research design and analytics, including observational, experimental and quasi-experimental methods, machine learning and web scraping. As an adjunct faculty member, Dr. Chow teaches Business Statistics, Data Science, and Project Management courses for the Mathematical Sciences Department and the Management Department.

TonyAnthony (Tony) E. Kiszewski, ScD, is an Associate Professor in the Department of Natural and Applied Sciences at Bentley University. He received his ScD in Tropical Public Health from Harvard University, his MSc in Medical Entomology from Cornell University, and his BS in Entomology from Colorado State University. Outside of Bentley, Dr. Kiszewski is also a public health entomologist who dabbles in general infectious disease epidemiology and health policy issues. His research combines field studies in vector ecology with laboratory investigations and spatially explicit and agent-based computer simulations of infectious disease dynamics (including COVID-19). He is especially interested in malaria control and prevention. Joining Bentley in July 2006, Dr. Kiszewski teaches Public Health and Epidemiology, Global Health, Entomology, and Mathematical Modeling. His collaborations with the Center for Integration of Science and Industry began in April 2020, researching the rapid development of COVID-19 vaccines.



Cody A. Hyman, PhD, is a visiting professor with the Accounting Department and the Center for Integration of Science and Industry at Bentley University. She earned her PhD in Accounting and Information Assurance from the University of Maryland, researching the role of networks in information acquisition. She received her MA in Economics from The George Washington University and her BA in Economics and Sociology from Clark University. Joining Bentley in July 2021, her current research pertains to individual investors and firm interactions. 

Current Undergraduate Researchers
Henry Dao, Norayr Diloyan, Megan Forman, Alina Wang

Current Graduate Researchers
Sarah Al-Masri, Maggie Ye (Cornell University)